Evolus, Inc.

Evolus, Inc.

EOLS·NASDAQ

$6.03

-2.3%
HealthcareDrug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

At a Glance

Live Snapshot
Market Cap$397.10M
EPS-0.8000
P/E Ratio-7.54
Earnings Date08/04/2026

eols

Revenue

Last Annual Value

297.18M

3-Year CAGR

26%

5-Year CAGR

39%

10-Year CAGR

%

Evolus, Inc.

Evolus, Inc. Competitors Analysis of Revenue

EOLS · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
EOLS logo
Evolus, Inc.
NASDAQ:EOLS
297.18M
13.7%24.4%N/A 
NGNE logo
Neurogene Inc.
NASDAQ:NGNE
0.00
N/AN/AN/A
212.69M
4.4%17.6%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
89.06M
25.3%N/AN/A
2.44M
31.1%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
1.06B
0.4%-0.9%N/A
0.00
N/AN/AN/A
236.35M
16.7%19.2%20.3%
502.73M
15.7%19.9%N/A
Evolus, Inc.

Evolus, Inc. Fair Value Envelope

EOLS · NASDAQ

Our analysis suggests that EOLS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.03, this represents a potential HIDDEN relative to our calculated worth for Evolus, Inc..

Intrinsic Value
Current Price: $6.03